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Background: The role of endogenous glucocorticoids (GC) in the initiation and maintenance of rheumatoid
arthritis (RA) remains unclear. We demonstrated previously that disruption of GC signalling in osteoblasts results in a
profound attenuation of K/BxN serum-induced arthritis, a mouse model of RA. To determine whether or not the
modulation of the inflammatory response by osteoblasts involves T cells, we studied the effects of disrupted
osteoblastic GC-signalling in the T cell-dependent model of antigen-induced arthritis (AIA).
Methods: Acute arthritis was induced in pre-immunised 11-week-old male 11β-hydroxysteroid dehydrogenase type
2 transgenic (tg) mice and their wild-type (WT) littermates by intra-articular injection of methylated bovine serum
albumine (mBSA) into one knee joint. Knee diameter was measured every 1–2 days until euthanasia on day 14 post
injection. In a separate experiment, arthritis was maintained for 28 days by weekly reinjections of mBSA. Tissues
were analysed by histology, histomorphometry and microfocal-computed tomography. Serum cytokines levels were
determined by multiplex suspension array.
Results: In both short and long term experiments, arthritis developed in tg and WT mice with no significant
difference between both groups. Histological indices of inflammation, cartilage damage and bone erosion were
similar in tg and WT mice. Bone volume and turnover at the contralateral tibia and systemic cytokine levels were
not different.
Conclusions: Acute murine AIA is not affected by a disruption in osteoblastic GC signalling. These data indicate
that osteoblasts do not modulate the T cell-mediated inflammatory response via a GC-dependent pathway.
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OsteoblastsBackground
It is unknown whether and how endogenous glucocorti-
coids (GC) contribute to the initiation and maintenance of
rheumatoid arthritis (RA) and other inflammatory diseases
[1-7]. We previously studied the role of endogenous GC
in the K/BxN serum-induced arthritis mouse model of RA
[8]. This model is T cell-independent as arthritis is elicited* Correspondence: cornelia.spies@charite.de
1Department of Rheumatology and Clinical Immunology, Charité –
Universitätsmedizin Berlin, Charitéplatz 1, D-10117 Berlin, Germany
2Bone Research Program, ANZAC Research Institute, Concord Repatriation
Hospital, The University of Sydney, Hospital Road, Concord Sydney, NSW
2139, Australia
Full list of author information is available at the end of the article
© 2014 Spies et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
waiver (http://creativecommons.org/publicdom
stated.by antibodies even if the recipients are devoid of lympho-
cytes [9,10]. Immune complexes of arthritogenic anti-
glucose-6-phosphate isomerase autoantibodies attract and
activate neutrophils and macrophages at the cartilage sur-
face through Fc receptor binding (particularly FcγRIII)
and activation of complement factors from the initial part
of the alternative complement pathway [11-15]. This in-
duces the release of pro-inflammatory cytokines including
interleukin (IL)-1 and tumour necrosis factor-α [16].
We have recently demonstrated that inactivation of en-
dogenous glucocorticoids in osteoblasts by overexpression
of the GC-inactivating enzyme, 11β-hydroxysteroid de-
hydrogenase type 2 (11β-HSD2), results in attenuation oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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http://www.biomedcentral.com/1471-2474/15/31K/BxN serum-induced arthritis [8]. These findings indi-
cated an immunostimulatory role of endogenous gluco-
corticoids and suggested that osteoblasts modulate the
immune-mediated inflammatory response via a GC-
dependent pathway. While K/BxN serum-induced arthritis
is principally a T cell-independent model of rheumatoid
arthritis, osteoblasts and osteoblastic GC-signalling may
or may not modulate the T cell-mediated inflammatory re-
sponse in other models of arthritis. For example, the
crosstalk between T cells and osteoblasts is known to be
important in intermittent parathyroid hormone induced
bone formation, involving Wnt signalling by Wnt10b [17],
which we have previously shown to be GC-dependent in
osteoblasts during development [18]. Osteoblasts interact
with T cells also by the production of cytokines such as IL-
6 [19], and IL-6 expression in osteoblasts is likely to be
GC-regulated [20].
In order to test whether or not the modulation of the in-
flammatory response by osteoblasts involves T cells, we
studied the effects of disrupted osteoblastic GC-signalling
in the T cell-dependent model of antigen-induced arthritis
(AIA) [21,22]. In this model, an adaptive immune re-
sponse is initiated by immunisation against the non-self
antigen methylated bovine serum albumine (mBSA). Local




Disruption of GC signalling in mature osteoblasts and os-
teocytes was achieved through transgenic overexpression
of the GC-inactivating enzyme, 11β-hydroxysteroid de-
hydrogenase type 2 (11β-HSD2), under the control of the
osteoblast-specific 2.3-kb collagen type Iα1 promotor
(Col2.3-11β-HSD2-transgenic mice). Animals were gener-
ated [23] and characterised as described previously
[18,23-25], and generously provided by Dr Barbara Kream,
University of Connecticut, USA). Mice were maintained at
the animal facilities of the ANZAC Research Institute, in
accordance with Institutional Animal Welfare Guidelines
and according to an approved protocol. An ethics approval
for the use of animals was obtained from the Sydney Local
Health District Animal Welfare Committee.
Initiation and clinical assessment of antigen-induced
arthritis
Immunisation
Antigen-induced arthritis (AIA) in mice was induced fol-
lowing established protocols [26,27]. Eight-week-old male
Col2.3-11β-HSD2 transgenic (tg) mice and their wild-type
(WT) littermates were immunised by subcutaneous injec-
tion of 100 μg methylated bovine serum albumin (mBSA)
(on day −21) (Sigma, Castle Hill, Australia), dissolved in
50 μl of phosphate-buffered saline (PBS) and emulsified in50 μl of Freund’s complete adjuvant (CFA) (Sigma), into
both flanks (50 μg each). A second injection of the same
dose was given 7 days later (on day −14) by subcutaneous
injection into the tail base. For control purposes, both
groups – arthritic and control animals – were immunised.
Mice were randomised to the respective groups matched
for body weight and litter.Induction of acute AIA
AIA was induced by intra-articular injection on day 0 in
Col2.3-11β-HSD2 tg mice (n = 17) and their WT litter-
mates (n = 17). Mice were anaesthetised with isoflurane
(inhalation anaesthetic), and a total of 10 μg mBSA in 5 μl
sterile PBS was injected intra-articularly through the patel-
lar ligament into the right knee joint with a Hamilton syr-
inge and a 251/2 gauge needle. Concurrently, tg (n = 14)
and WT mice (n = 15) receiving 5 μl of sterile PBS by
intra-articular injection, served as controls (CTR). Body
weight and knee joint swelling were assessed every 1–
2 days from the time of induction (day 0) up to day 14.
Knee joint diameter was measured using a Vernier caliper.
The maximum medial-to-lateral diameter was defined at
the widest point of each knee joint. Knee joint swelling
was calculated as the absolute difference to the knee joint
diameter measured at baseline before arthritis induction.
Mice were euthanised on day 14 for tissue and blood col-
lection. Tissue of n = 5 mice of each group was preserved
for future RNA analysis. Histological, microfocal-computed
tomography (micro-CT), histomorphometric and serum
cytokine analyses were performed in the remaining tg and
WTarthritic and control mice, respectively.Induction of prolonged arthritis
Prolonged antigen-induced arthritis was induced in order
to study longer-term effects of AIA on arthritis and bone.
Since we wished to keep mechanical damage, potentially
induced by repeated intra-articular injections, to a mini-
mum, we induced flare-ups by intravenous re-injections of
mBSA, as has been described before [26,28]. Following in-
duction of acute AIA in Col2.3-11β-HSD2 tg mice and
their WT littermates, arthritic mice received repeated
intravenous injections of 300 μg mBSA (in 200 μl PBS) on
days 7, 14 and 21 [26,28]. Tg and WT control mice re-
ceived 200 μl sterile PBS intravenously (n = 10 per arthritic
group, n = 9 per control group) at the same time points.
Body weight and knee joint swelling were assessed as de-
scribed above. Mice were sacrificed on day 28. During the
flare-up experiment, 8 mice were excluded [5 anaphylactic
reactions (all in mBSA-injected mice), 3 mechanical
damages (2 in arthritic mice, 1 in control)]. The relatively
high frequency of anaphylactic reactions was unexpected
[26,28]. The remaining arthritic tg (n = 6) and WT mice
(n = 7), and control tg (n = 9) and WT (n = 8) mice were
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and serum cytokine analyses.
Tissue collection and specimen preparation
Blood for serum analyses was collected by cardiac punc-
ture. Right and left knee joints (including tibia and distal
femur) of each mouse were dissected and fixed for
48 hours in 4% paraformaldehyde/PBS. After micro-CT
analyses, the knees and tibiae were decalcified in 10% eth-
ylenediaminetetraacetic acid (EDTA) and embedded in
paraffin. Serial 4-μm sections were stained with haema-
toxylin and eosin (H&E) for general histological evaluation
and with toluidine blue for assessment of cartilage degrad-
ation and proteoglycan loss [8]. To identify osteoclasts,
sections were stained for tartrate-resistant acid phosphat-
ase (TRAP) using naphthol-AS-MX phosphate (Sigma) as
a substrate and fast red violet LB salt (Sigma) as a detec-
tion agent for the reaction product [8].
Histopathological scoring
Sections of knee joints were stained with H&E or toluidine
blue or TRAP, and scored by 3 independent and blinded
investigators (EW, CS, JT) for synovitis, soft tissue inflam-
mation, joint space exudate, cartilage degradation/proteo-
glycan loss, and bone erosion, according to an established
semi-quantitative scoring system [27].
Micro-CT
Left tibiae analysis was performed using a SkyScan 1172
scanner (SkyScan, Kontich, Belgium). Scanning was done
at 100 kV and 100 μA, using a 1-mm aluminium filter with
the exposure set to 590 msec. In total, 1,800 projections
were collected at a resolution of 6.93 μm/pixel. Recon-
struction of sections was done using a modified Feldkamp
cone-beam algorithm, with the beam hardening correction
set to 50%. To quantify the trabecular morphometry of
the proximal tibia, CTAnalyser software version 1.02 (Sky-
Scan) was used. The greyscale index was set from 75 to
255 per cent. 3D-methods were used in the calculation al-
gorithms. The volume of interest was selected within the
endosteal borders, 1–2.3 mm below the growth plate [8].
Slide thickness was 7 μm.Histomorphometry
Bone histomorphometry of the left proximal tibial meta-
physis was conducted in single measurements on 4-μm sec-
tions stained with TRAP or H&E, using OsteomeasureXP
v.3.2.1.5 (OsteoMetrics, Inc., Decatur, GA, USA). The re-
gion of interest was a 1.5 x 1-mm area of cancellous bone
located 0.3 mm below the growth plate of the tibia [8].
Osteoclast number and osteoclast surface relative to bone
surface were measured (400x magnification). Osteoblasts
were identified by morphology (400× magnification).Measurement of serum cytokines
Serum levels of tumour necrosis factor α (TNF-α),
interferon-γ (IFN-γ), murine interleukin-1α (IL-1α), IL-1β,
IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12(p40), IL-12
(p70), IL-13, IL-15, IL-17A, IL-18, monocyte chemotactic
protein-1 (MCP-1), macrophage inflammatory proteins 1α
(MIP-1α), 1β (MIP-1β) and 2 (MIP-2), regulated upon ac-
tivation normal T cell expressed and secreted (RANTES),
keratinocyte-derived cytokine (KC), monokine-induced
by interferon-gamma (MIG), eotaxin, leukaemia inhibitory
factor (LIF), basic fibroblast growth factor (basic-FGF),
platelet-derived growth factor homodimer (PDGF-BB),
vascular endothelial growth factor (VEGF), granulocyte
colony-stimulating factor (G-CSF), granulocyte macrophage
colony-stimulating factor (GM-CSF), and macrophage
colony-stimulating factor (M-CSF) were all determined
using the cytometric bead array technique [29]. Premixed
cytokine assays (Bio-Rad, Munich, Germany) were used ac-
cording to the manufacturer’s instructions. Data acquisition
was conducted using the Bio-Plex suspension system (Bio-
Rad). Each sample was read in duplicate and measured
against the mean of two dilution rows. For analysis, values
below the detection limit were substituted with the value of
50% of the detection limit.
Statistical analysis
For comparisons of normally distributed data between 2
experimental groups, the t-test was used. Unless otherwise
stated, values are the mean and standard deviation (SD) or
standard error of the mean (SEM). Non-normally distrib-
uted data were compared between two groups using the
Mann–Whitney test. In the case of planned multiple com-
parisons for the same parameter multiple two-group com-
parisons were conducted only if the Kruskal-Wallis test
over all 4 groups was significant. Here the Bonferroni cor-
rection was used to adjust the significance level to α* =
0.0125 for 4 parallel tests (WT-CTR versus tg-CTR, WT-
AIA versus tg-AIA, WT-CTR versus WT-AIA, tg-CTR
versus tg-AIA). The clinical results as obtained over the
14-day or 28-day experimental course were modelled by a
generalised linear model with repeated-measures analysis.
The PAIA values given are for the interaction day × group
of within-subjects effects from the repeated-measures ana-
lysis, indicating differences in the time course of trans-
genic and WT arthritic mice. IBM SPSS Statistics version
19 (IBM, Armonk, NY, USA) was used for statistical ana-




On day 0, prior to the intervention, body weights of WT
and tg littermates were similar (mean ± SD 37.6 ± 3.6 g vs.
36.9 ± 3.1 g; P = 0.454). From day 0 on, body weight gain
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0.077] as well as in arthritic WT compared with arthritic
tg mice [PAIA = 0.908].
Knee joint swelling
Knee joint diameter prior to arthritis induction (day 0) did
not differ between WT and tg mice (mean ± SD 4.058 ±
0.206 mm and 4.057 ± 0.209 mm, respectively; P = 0.979).
Both WT and tg mice treated with mBSA developed acute
arthritis with significant knee joint swelling in comparison
to controls [P < 0.001], with maximum values on day 1 post
injection (mean increase in joint diameter ± SD: +1.07 ±
0.53 mm and +0.96 ± 0.58 mm, respectively). Following day
1, knee joint swelling resolved over time in both groups.
There was no statistically significant difference in knee joint
swelling between arthritic WT and tg mice [PAIA = 0.468]
(Figure 1A).
Histopathological assessment of arthritis
Clinical findings were corroborated by corresponding
histological indices of inflammation, cartilage damage
and bone erosion. Inflammatory activity on day 14 after
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Figure 1 Clinical assessment of inflammation in arthritic mice injected
injected with mBSA on day 0 (AIA) and control mice were injected with ph
swelling from day 1 to day 14 post intra-articular injection. Knee diameter
the difference to the knee diameter at day 0 (before arthritis induction) for ea
Methods); the PAIA value indicates the significance of the difference in variatio
(TG) mice treated with mBSA. (B) Means and SEM for knee joint swelling from
induced by intravenous mBSA injections on days 7, 14, 21 (arrows). Knee diam
significance derived by repeated-measures analysis between WT AIA mice andcompared to WT AIA mice (Figure 2A, B, and C). Simi-
larly, cartilage degradation and proteoglycan loss in the
knee joints were not different in tg AIA mice when com-
pared to WT AIA mice (Figures 2D, E, and F). There was
no significant difference between tg and WT AIA mice,
neither in the single histological scores for synovitis, joint
space exudate, soft tissue inflammation, cartilage degrad-
ation/proteoglycan loss, and bone erosion, nor in the total
histology score (Figures 2G and H).
Micro-CT
To quantify the systemic effects of inflammation on bone
metabolism, the contralateral (left) proximal tibia (i.e., a
skeletal region remote from the actual site of inflamma-
tion) was analysed by micro-CT. No statistically significant
difference was detectable between arthritic and control
mice, as well as between tg and WT mice in terms of the
bone volume fraction (bone volume/tissue volume [BV/
TV]), trabecular number and trabecular separation. This
indicates that locally restricted AIA does not affect bone
morphology systemically, at least not after 14 days. There
was a statistical difference in trabecular thickness with



















with mBSA and non-arthritic control mice. Arthritic mice were
osphate buffered saline (CTR). (A) Means and SEM for knee joint
was measured every 1–2 days and knee joint swelling was calculated as
ch day. A repeated-measures analysis was performed (see Materials and
n of knee joint swelling over time between wild-type (WT) and transgenic
day 1 to day 28, post intra-articular injection and three flare-up reactions
eter was measured every 1–2 days. The PAIA value represents the
transgenic AIA mice.





























































































Figure 2 Arthritis and cartilage damage in the knee joint 14 days post intra-articular injection. (A-F) Representative histologic sections of
knee joints from wild-type (WT) and transgenic mice (TG) treated with mBSA (AIA) and from non-arthritic wild-type control mice (CTR). Both
inflammatory activity and cartilage damage were similar in transgenic mice and wild-type mice treated with mBSA. (A–C) Hematoxylin and eosin
staining. Arrows show synovitis, joint space exudate and soft tissue inflammation. Bars = 100 μm. (D–F) Toluidine blue staining. Arrows show
proteoglycan loss of articular cartilage. Bars = 100 μm. (G-H) Histopathology scores (G single, H total) in mBSA-treated mice (AIA) 14 days post
injection. The knee joints of all mice were assessed as described in Materials and Methods. Bars show the mean ± SEM. Findings in arthritic
wild-type AIA mice and arthritic transgenic AIA mice for single scores were compared by Mann–Whitney test. Total scores were compared
between the 4 groups with adjustment for 4 parallel tests (α* = 0.0125). NS = not significant (see Figure 1 for other definitions).
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Histomorphometry was performed at the contralateral
(left) proximal tibiae of mice. Mean osteoclast surface
per bone surface and mean osteoclast number per bone
surface as well as mean osteoblast surface per bone sur-
face were not significantly different in arthritic versus
non-arthritic mice, nor was there any difference seen be-
tween tg and WT mice (Figure 3B). This indicates that
short-term, monarticular inflammation has little or no
effect on systemic bone turnover.
Serum levels of cytokines
The serum levels of 32 cytokines, chemokines and growth
factors were determined in AIA and control mice. There
was a statistically significant difference between AIA WT
and tg mice for IL-1α, IL-12 (p70) and IL-13 on day 14.
However, a statistically significant difference between arth-
ritic and control mice was not detectable (Table 1). There
were no significant differences in TNF-α, IL-1β, IL-9, IL-
10, IL-12 (p40), IL-15, IL-18, MCP-1, MIP-1α, MIP-1β,RANTES, KC, MIG, Eotaxin, LIF, basic-FGF, PDGF-BB,
VEGF, M-CSF or G-CSF levels between WT and tg mice,
or between AIA and control mice. Serum concentrations
of IFN-γ, IL-2, IL-3, IL-4, IL-5, IL-6, IL-17A, MIP-2, and




Since in acute AIA, arthritis tended to resolve from day
2 p.i. onwards, we further tested our hypothesis in a
model of prolonged antigen exposure, where inflamma-
tion was maintained for up to 28 days through weekly
injections of mBSA. Body weight at baseline was signifi-
cantly higher in WT (mean ± SD: 38.6 ± 3.4 g) compared
to tg mice (36.1 ± 1.4 g; P = 0.016). After each flare-up
reaction, a minor weight loss (<10%) was observed in
both arthritic and control mice [P = 0.314]. The degree






















































































































































































































Figure 3 Micro-CT and histomorphometric analysis of the contralateral proximal tibia 14 days post injection of mBSA. Bone turnover
was measured at a location distant to the site of active inflammation to assess the systemic effects of joint inflammation. (A) Micro-CT.
The bone volume fraction (bone volume/tissue volume (BV/TV]), trabecular number (Tb.N), trabecular separation (Tb.Sp), and trabecular
thickness (Tb.Th) are shown for bones harvested. Bars show the mean ± SEM. Findings between the 4 groups were compared using
the Mann–Whitney-Test with adjustment for 4 parallel tests (α* = 0.0125). NS = not significant (see Figure 1 for other definitions).
(B) Histomorphometric quantification. Bone resorption, shown as osteoclast surface/bone surface (Oc.S/BS) and osteoclast number/bone
surface (N.Oc/BS), respectively. Bone formation, shown as osteoblast surface/bone surface (Ob.S/BS). Bars show the mean ± SEM. Findings
between the 4 groups were compared by using the Mann–Whitney test with adjustment for 4 parallel tests (α* = 0.0125). NS = not
significant (see Figure 1 for other definitions).
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Knee diameter prior to induction of arthritis (day 0)
was not different between WT and tg mice (mean ± SD
3.88 ± 0.07 mm and 3.85 ± 0.08 mm, respectively; P =
0.203). As observed in acute AIA, acute arthritis with
significant knee joint swelling in comparison to controls
developed in both WT and tg mice in response to the
initial injection of mBSA [P < 0.001]. Maximum knee
joint swelling was observed on day 1 post injection. Fur-
ther flare-up reactions were observed on days 8, 15 and
22. However, there was no statistically significant differ-
ence in knee joint swelling between arthritic WT and tg
mice over the observation period of 28 days [PAIA =
0.456] (Figure 1B).Histopathological assessment of inflamed joints
Histological inflammatory activity, cartilage degradation
and bone erosion, as assessed on day 28, were not seen
to be different between tg and WT AIA mice (Figure 4).
Micro-CT
In micro-CT analysis of the contralateral tibia we found
no statistically significant differences between arthritic and
control mice regardless of the genotypes in terms of BV/
TV (WT CTR 10.1 ± 2.0%; WT AIA 10.6 ± 1.6%; tg CTR
9.3 ± 3.1%; tg AIA 8.7 ± 2.8%), trabecular number (WT
CTR 1.649 ± 0.405/mm; WT AIA 1.861 ± 0.287/mm; tg
CTR 1.554 ± 0.490/mm; tg AIA 1.345 ± 0.435/mm) and
trabecular separation (WT CTR 342.6 ± 123.7 μm; WT
Table 1 Serum cytokine levels in control mice and arthritic AIA mice
Cytokine Control mice, day 14 AIA mice, day 14
Wild-type (n = 15) Transgenic (n = 14) Wild-type (n = 17) Transgenic (n = 17)
TNF-α (pg/ml) 36 (36–408) 36 (36–36) 409 (36–476) 36 (36–341)
IL-1α (pg/ml) 67 (58–71) 5 (5–64) 89 (54–97) 44 (5–66)#
IL-1β (pg/ml) 558 (46–1,050) 46 (46–1,097) 574 (46–1,397) 46 (46–431)
IL-6 (pg/ml) 6 (6–6) 6 (6–6) 6 (6–6) 6 (6–6)
IL-10 (pg/ml) 50 (5–111) 5 (5–61) 72 (46–107) 50 (5–64)
IL-12 (p40) (pg/ml) 175 (114–222) 131 (114–183) 193 (147–272) 152 (130–224)
IL-12 (p70) (pg/ml) 149 (13–202) 108 (13–149) 162 (123–236) 108 (13–130)#
IL-13 (pg/ml) 45 (45–964) 45 (45–523) 852 (361–1470) 45 (45–45)#
M-CSF (pg/ml) 204 (119–593) 548 (158–612) 295 (115–481) 488 (146–608)
G-CSF (pg/ml) 121 (13–257) 59 (13–140) 165 (13–216) 105 (13–189)
Cytokine Control mice, day 28 AIA mice, day 28
Wild-type (n = 8) Transgenic (n = 9) Wild-type (n = 7) Transgenic (n = 6)
TNF-α (pg/ml) 1,361 (903–2310) 1,255 (655–1468) 1,255 (655–1468) 1,577 (848–1685)
IL-1α (pg/ml) 9 (9–9) 9 (9–9) 9 (9–9) 9 (9–9)
IL-1β (pg/ml) 14 (14–144) 14 (14–14) 14 (14–979) 517 (14–1073)
IL-6 (pg/ml) 6 (6–6) 6 (6–6) 6 (6–6) 6 (6–6)
IL-10 (pg/ml) 56 (49–68) 44 (44–54) 49 (40–54) 68 (35–130)
IL-12 (p40) (pg/ml) 98 (90–136) 70 (56–103) 110 (81–147) 83 (72–90)
IL-12 (p70) (pg/ml) 8 (8–8) 8 (8–8) 8 (8–8) 86 (8–105) §, #
IL-13 (pg/ml) 101 (8–253) 8 (8–8) 160 (113–254) 254 (66–1374) §
M-CSF (pg/ml) 95 (85–103) 106 (81–112) 86 (79–120) 88 (77–470)
G-CSF (pg/ml) 12 (12–12) 12 (12–12) 12 (12–12) 12 (12–12)
Values indicated are the median values (interquartile range). Findings between groups were compared using the Kruskal-Wallis test, followed by multiple
two-group comparisons. The Bonferroni correction was used to adjust the significance level for 4 parallel comparisons (α* = 0.0125). TNF-α = tumour necrosis factor
α; IL-1α = interleukin-1α; M-CSF =macrophage colony-stimulating factor; G-CSF = granulocyte colony-stimulating factor.
Wild-type versus transgenic CTR mice: none.
#Wild-type versus transgenic AIA mice: IL-1α p14 = 0.008; IL-12 (p70) p14 = 0.010 and p28 = 0.009; IL-13 p14 = 0.001.
CTR versus AIA wild-type mice: none.
§CTR versus AIA transgenic mice: IL-12 (p70) p28 = 0.001; IL-13 p28 = 0.008.
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392.8 ± 125.6 μm) after repeated flare-up reactions, except
for a higher trabecular thickness in tg than in WT AIA
mice (tg AIA 64.5 ± 4.5 μm vs. WT AIA 57.0 ± 4.1 μm,
p = 0.005; WT CTR 62.2 ± 5.8 μm; tg CTR 59.8 ± 3.1 μm).
Bone histomorphometry
Histomorphometric analysis of the contralateral tibia
demonstrated no statistically significant differences in
terms of osteoclast number per bone surface (WT CTR
4.8 ± 1.6/mm; WT AIA 7.7 ± 2.6/mm; tg CTR 7.2 ± 1.7/
mm; tg AIA 6.0 ± 2.1/mm) and osteoblast surface per
bone surface (WT CTR 14.4 ± 3.6%; WT AIA 14.5 ±
5.0%; tg CTR 16.8 ± 3.6%; tg AIA 17.1 ± 5.7%) after re-
peated flare-up reactions, except for a higher mean
osteoclast surface per bone surface in tg control mice
than in WT control mice (tg CTR 9.4 ± 2.6% vs. WT
CTR 5.8 ± 1.7%, p = 0.009; WT AIA 9.6 ± 3.9%; tg AIA
7.2 ± 2.4%).Serum levels of cytokines
There was a statistically significant difference between
AIA WT and tg mice for IL-12 (p70) on day 28 (Table 1).
However, a statistically significant arthritis effect was de-
tectable for IL-12 and IL-13 levels between tg AIA and
control mice only, whereas in WT mice there was no dif-
ference between arthritic and non-arthritic mice. There
were no significant differences in TNF-α, IL-1β, IL-9, IL-
10, IL-12 (p40), IL-15, IL-18, MIP-1α, MIP-1β, RANTES,
KC, MIG, Eotaxin, basic-FGF, PDGF-BB, VEGF or M-CSF
levels between WT and tg mice, or between AIA and con-
trol mice. Serum concentrations of IFN-γ, IL-2, IL-3, IL-4,
IL-5, IL-6, IL-17A, MIP-2, GM-CSF and MCP-1, LIF and
G-CSF were below the detection limit in the majority of
mice.
Discussion
In sharp contrast to our previous findings in K/BxN serum-




























































































Figure 4 Arthritis and cartilage damage in the knee joint on day 28 of prolonged arthritis. Mice received intra-articular injection on day 0
and three repeated intravenous boosts with antigen or PBS on days 7, 14, 21. (A–F) Representative histologic sections of knee joints from
wild-type (WT) and transgenic (TG) mice treated with mBSA (AIA) and from non-arthritic wild-type control mice (CTR). Both inflammatory
activity and cartilage damage were similar in TG and WT mice. (A–C) Haematoxylin and eosin staining. Arrows show synovitis and soft tissue
inflammation. Bars = 100 μm. (D–F) Toluidine blue staining. Arrows show proteoglycan loss of articular cartilage. Bars = 100 μm. (G-H) Histopathology
scores (G single, H total) in mBSA treated mice (AIA) on day 28 post intra-articular injection and three flare-up reactions. The knee joints of all mice were
assessed as described in Materials and Methods. Bars show the mean ± SEM. Findings in arthritic wild-type and transgenic mice for single
scores were compared by Mann–Whitney test. Total scores were compared between the 4 groups with adjustment for 4 parallel tests
(α* = 0.0125). NS = not significant.
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http://www.biomedcentral.com/1471-2474/15/31murine antigen-induced arthritis (AIA) is unaffected by dis-
ruption of GC signalling in osteoblasts. The most import-
ant variables for the decision to reject the hypothesis were
clinical signs and histology. Neither in acute nor in pro-
longed AIA did any clinical signs of arthritis differ signifi-
cantly between transgenic and WT mice. The impression
that the WT- and tg-mice in the short-time and long-time
experiments react differently to arthritis induction (Figure 1)
is due to the lower number of animals in the long-time ex-
periments. This was confirmed via histological assessment
of inflammatory activity, cartilage degradation or bone ero-
sion, where also no significant differences were detectable
in both experiments.
The immunological and inflammatory profiles of AIA dif-
fer profoundly from those of K/BxN arthritis (Table 2). In
AIA, disruption of GC-signalling in osteoblasts is not rele-
vant, probably because the antibody- mediated inflamma-
tory response is of minor importance and the T cell
response overcomes other effects. Antigen-specific T cells,in particular CD4+ T helper cells, generated within the
adaptive immune response initiated through immunisation,
play a major role in AIA as arthritis in this model cannot be
induced in T cell-deficient mice [21,22,30]. The antibody-
mediated inflammatory response is present in AIA as well,
but apparently this is of minor importance here. This is evi-
denced by the observations that (i) mBSA antibodies-
containing serum can only induce very weak arthritis and
(ii) antibody-producing B cells are not at all required for in-
duction of arthritis [21,22,30]. The mBSA challenge induces
a significant neutrophil migration which peaks at 24 hours
and subsides by seven days after challenge [31,32]. Fc Recep-
tors are involved in this activation [33,34], but – in contrast
to exclusively antibody-mediated arthritis models – comple-
ment appears to play a minor role. This conclusion has been
derived from findings which demonstrate that flare-up reac-
tions of AIA are complement-independent, and that neutro-
phils occur in the synovial tissue of complement-depleted
mice as well [35].
Table 2 Immunological and inflammatory profiles of AIA and K/BxN models
Compartment Antigen-induced arthritis (AIA) K/BxN serum-induced arthritis (KRN)
T cells T cell-dependent [21,22,30] T cell-independent [9]
B cells B cell-independent [22] B cell-independent [9]
Antibodies Antibodies unnecessary/insufficient to induce
arthritis to the full extent [21,22,30]
Antibodies necessary/sufficient to induce
arthritis in full extent [9]
Complement Complement-independent [31] Complement-dependent [12]
Fc receptors FcγR important [32,33] FcγR-dependent [12]
Neutrophils, macrophages Neutrophils important [34,35], but
complement-independent [31]
Neutrophil-dependent, macrophage-dependent [13,14]
Cytokines IL-1, TNF-α, IL-6, IL-17, RANKL important [22,36] IL-1-, TNF-α-dependent [16] IL-6-, osteopontin-independent [16,37]
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http://www.biomedcentral.com/1471-2474/15/31In contrast, in antibody-mediated arthritis, such as K/
BxN serum-induced arthritis, T cells are not required.
Arthritis is provoked by the antibodies even if the recipi-
ents are devoid of lymphocytes [9,10]. Immune com-
plexes of arthritogenic auto-antibodies act through Fc
receptors and the complement network [11,12], activat-
ing neutrophils and macrophages which have been
shown to be essential for induction of K/BxN serum-
induced arthritis (whereas mast cells have recently been
found to be apparently not mandatory) [13-15,38].
Therefore, our results suggest that the GC-dependent
pathway by which osteoblasts modulate the inflamma-
tory response is T cell-independent. Osteoblasts appear
to impact the immune complex-mediated inflammatory
response via a GC-dependent pathway.
The alternative complement pathway is essential in K/
BxN serum-induced arthritis [12]. Complement factors
are mainly generated in the liver. However, osteoblasts
have been shown to express complement factors [39], and
in endothelial cells, complement factor expression has
been found to be GC-dependent [40]. Hence, osteoblasts
may produce alternative complement factors in a GC-
dependent way (e.g. C3, factor B, factor H), and reduction
of these osteoblastic alternative complement factors could
be responsible for attenuation of arthritis in Col2.3-11β-
HSD2-transgenic mice. Other pro-inflammatory factors in
antibody-mediated arthritis – which may be generated by
osteoblasts in a GC-dependent way – are urokinase-type
plasminogen activator (u-PA) [41-43], matrix metallopro-
teinases (MMP) [18,43] and macrophage migration inhibi-
tory factor (MIF) [44-46]. Osteopontin and IL-6 are rather
unlikely to be responsible because they play no essential
role in K/BxN arthritis [16,37].
We found no differences in multiplex analysis of serum
cytokine levels between arthritic and control mice for WT
mice, and only IL-1α, IL-12 p40 and IL-13 for tg mice. This
is in accordance with a recently published follow up (from
7 hours to 14 days) multiplex analysis of 24 cytokines in
synovial fluid and sera of rats developing antigen-induced
arthritis [47]. Cytokine concentrations in sera also showed
only little variation here, whereas between cytokineconcentrations in arthritic synovial fluid and histological or
clinical parameters some correlations were established [47].
We agree with the authors, that “such results are consistent
with the local and monarticular nature of AIA, rendering
the amount of cytokines produced within a single diseased
joint prone to be reduced by degradation in the lymphatic
system or by dilution into the bloodstream or both” [47].
The relevance of the differences for IL-1α, IL-12 p40 and
IL-13 between AIA WTand tg mice remains unclear. IL-12
p40 and IL-13 levels were lower in tg mice in comparison
to WT mice after 14 days, but paradoxically higher after
28 days. In our study of K/BxN serum-induced arthritis, IL-
12 p40 levels had not been different, and IL-6 and M-CSF
levels tended to be altered in tg mice in comparison to WT
mice (IL-1α and IL-13 levels were not determined) [8].
There is indeed evidence for a (endogenous) glucocorticoid
modulation of IL-1α, IL-12 p40 and IL-13 [48-51]; however,
such a modulation in osteoblasts apparently is of no rele-
vance for AIA.
We did not measure a decrease of BV/TV or an increase
in osteoclast covered bone surface due to AIA-arthritis in
WT-mice compared to the control group of WT-mice,
probably because μCT and histomorphometric measure-
ments were done at the contralateral tibia. Even if the se-
verity of arthritis at the arthritic knee in this model
reached a normal extent, comparable to what is known in
literature [52], apparently there are no systemic effects on
bone due to the monarticular nature of AIA. This is in line
with the cytokine measurements (see above). In our stud-
ies of K/BxN arthritis we had seen a systemic effect of
arthritis on bone in μCT and histomorphometry at the
tibia in WT mice, which was prevented in tg mice [8]. The
extent of erosions achieved in the arthritic knee in AIA
was low in short and long-term experiments, consistent
with previous investigations [53,54].
Conclusions
To summarise, murine AIA is not affected by disruption
of GC signalling in osteoblasts. Our findings suggest that
osteoblasts do not modulate the T cell-mediated inflam-
matory response via a GC-dependent pathway.
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